Mindy Hamlin | July 20, 2018
Three North Carolina companies joined the prestigious list of participants in the 2018 MedTech Innovator Accelerator and Showcase programs. The Los Angeles-based non-profit is a global competition and accelerator for medical device, digital health and diagnostic companies.
Each year, the nonprofit selects 50 early- and mid-stage companies from several countries to participate in its four-month program, featuring the industry’s most promising medical technologies from around the world.
The 2018 cohort features 25 early-stage and 25 mid-stage companies with transformative device, diagnostic, and digital health technologies. Companies are chosen to participate in either the organization’s Showcase or Accelerator program.
North Carolina-based RFPi and Physcient, both portfolio companies of the North Carolina Biotechnology Center, were selected to participate in MedTech’s four-month Showcase program for mid-stage companies. Pneumonics, of Durham, was selected to compete in its Accelerator program.
The program will culminate September 24 to 26 in Philadelphia, where all 50 companies will present in Showcase panels and exclusive partnering at The MedTech Conference, powered by AdvaMed. From the Accelerator cohort, four companies will advance to compete in the grand finale where the vote of the audience at the largest gathering of medtech industry leaders in North America will determine the winners, with more than $500,000 in cash prizes, scholarships, and in-kind services. Multiple awards will also be given for incubator spaces at JLABS, Magnify at CNSI, and the Gore Innovation Center.
Greenville-based RFPi develops medical imaging technology that provides immediate visualization and quantification of blood flow and perfusion without the need for injections, dyes, radiation or direct patient contact. Durham-based Physcient is the developer of surgical dissection technology that makes surgery faster and safer than existing technology, especially laparoscopic or “key hole” surgery. Pneumonics develops home-based opioid overdose and hospital respiratory monitoring.